{"name":"Acer Therapeutics","slug":"acer","ticker":"ACER","exchange":"NASDAQ","domain":"acertx.com","description":"Acer Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. The company's pipeline includes products for the treatment of rare metabolic disorders. Acer Therapeutics has a strong presence in the rare metabolic disease market with a focus on developing innovative treatments for patients with limited options. The company's lead product, ACER-001, is a proprietary formulation of sodium phenylacetate and sodium benzoate for the treatment of hyperammonemia associated with inborn errors of metabolism.","hq":"Newton, MA","founded":0,"employees":"","ceo":"Chris Schelling","sector":"Rare Metabolic Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$85M","metrics":{"revenue":28000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":11924837,"netIncome":-26237315,"cash":11624226,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"ACER-001 patent cliff ($0.0B at risk)","drug":"ACER-001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Acer Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Acer Therapeutics reported its financial results for the fourth quarter and full year 2023, with a net loss of $14.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Acer Therapeutics Announces Exclusive Distribution Agreement with SIFI for ACER-001 in Italy","summary":"Acer Therapeutics announced an exclusive distribution agreement with SIFI for ACER-001 in Italy.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"regulatory","headline":"Acer Therapeutics Receives FDA Orphan Drug Designation for ACER-001 for the Treatment of Urea Cycle Disorders","summary":"Acer Therapeutics received FDA orphan drug designation for ACER-001 for the treatment of urea cycle disorders.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPSXMtUXZUYkczMmQtU3RYRkZDT0d3S2hQeUhwUDlUUzh5MDloWTlGb2NncWw4dU1ucEJ2aU1KWTFRYzNBQXFIWHFDZ1FydFhwUjNRdFZfcnNGb0Zja1R5NlRtT1ZhVGhQZWNQaU1DLVA3WGRWUWJjT3FLaWF0TUpLY1BXX3Q3RlZsTVZOZDQtaDJBOTdIV3ByX0FvOE5nc1hfa1NNYUNn?oc=5","date":"2025-08-13","type":"pipeline","source":"Investor's Business Daily","summary":"Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.' - Investor's Business Daily","headline":"Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.' - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBZMUpCZ1c5clNObmtydHdFWnNwUTRwX2lIQVdWRHZwSm9WQnZvM2N1S0lhUHdZcG9tZ2RaUDRfNm1oeTdYMTdld0pUODVzRzlaOVhXd0RSLWlmT1RRYkRIYm5CZmh6VHEwZnpUTWdwWkRhRk5sWUsxcWxR?oc=5","date":"2023-11-21","type":"deal","source":"Pharmaceutical Technology","summary":"Zevra Therapeutics completes Acer acquisition in $91m deal - Pharmaceutical Technology","headline":"Zevra Therapeutics completes Acer acquisition in $91m deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPb0xybEVYSnJzWE5ZSzdwUDQzWVpmdzhTNXRTbjVpbDd5TDhDeEc2NVdNZ0VRc25OSnYteWs3YUJhV0dsbl9hVG9udW1HV1NJUFMyTkVhNC1adGRES1RsbEFkX2R3MFliMW1YODZ2WjFOa2VlR09CUzBScGw1d2ktdW12dVFfMTR1cm5Qa3A2WTlkck5mQ2c?oc=5","date":"2023-11-20","type":"deal","source":"Contract Pharma","summary":"Zevra Therapeutics Acquires Acer Therapeutics - Contract Pharma","headline":"Zevra Therapeutics Acquires Acer Therapeutics","sentiment":"neutral"},{"date":"2023-11-20","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQNUROV1RPRWx3Y1ozT1Q0Qkx1R2JLYjZBUm94Z1JTc1hjTndFQUxBUzM4SVpZbURUOUhVR3prLTk2ZVg2alJ3aVJhejhCZXFWWE1MSUtWUUo5Q0NkNEtLWHA4MUhtS2pxOFpNMlBrS1MtTWZrSmJ0ZE9mckJXaDdXMXEyZ05fNG1tc1RDT0F3eF9LaWtfSUpCX1NMUGJTUGM0M0J2X2lJcVo0c2J2dnFkQmFsSHA?oc=5","date":"2023-08-31","type":"deal","source":"Pharmaceutical Technology","summary":"Zerva acquires Acer Therapeutics to bolster rare disease portfolio - Pharmaceutical Technology","headline":"Zerva acquires Acer Therapeutics to bolster rare disease portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPQnJtUXQydFdGb08zSTAxOEYtZjhCS3NiYTRsTDB5X2lENXIzTGs1MUNBRllqX3hNR1BRck5xZ0dka2FNU29xaUVyMGw3MWwwUHpQRjFSdXhBeEJqWTlTN2g2ZEFDTzNPVlZDZ3dmM21BMG9iaURqYk5lR3VoaGpjNWtIMWhYVUpVNTlDMkI3dW1MTWQ3cVA4ZmE4dmlUWTRlV19ucGpDbTk0dU43bjBJZg?oc=5","date":"2023-08-31","type":"deal","source":"Fierce Pharma","summary":"Zevra strikes $91M buyout of Acer to catapult itself into commercial rare disease space - Fierce Pharma","headline":"Zevra strikes $91M buyout of Acer to catapult itself into commercial rare disease space","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOczRoc2pxdUFpR2czNWN3ZlMyNDZ4QlBsZWZTb1JKdHdfM2VLODRCbF9aNWFrd1BTeEdlTHBNTXZMTHRNTEdFWUQ1R0RhSUlxS1hrQXQycjJ0X05oTTJua3lDVW9RbTk1dkZUTlV2MjFVZHd4S3EtMTgtUDdtYW1CM2E1eFFYYmxydk9kWDRrQWZRZkx4b09xOUxSTXlrMlA5ZWx0aXFObzYyaVhEMnVNdUduSFRycEREdXlGSGo3Z1dKd2VvTk9CTHZ5eEgwT19ZRHNULThIU1RweUpSdVA1OWgxYUxxdk9lSktJNHhpWFJaR1JXdEhianlFb3BZanEzc3hJWURpaGJScG1qOGV3NGdON3AtMDdUYVE?oc=5","date":"2023-08-31","type":"deal","source":"globenewswire.com","summary":"Zevra Therapeutics to Acquire Acer Therapeutics, Expanding - globenewswire.com","headline":"Zevra Therapeutics to Acquire Acer Therapeutics, Expanding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNc29EWjhxU0U0N210Sk9tVFF1RXpRenBkdTFZUjFhQjkzZ2ZFSnM2OG5ySTVwRklSUUR3MW5RdFNHZGJRd1BFM2YtTGpLZ193TUI2RDNYN3Z1ampzS3hudEhMeEhoR2NFRjZhS2xRUEpIOF9tR2tZRlI1MzJodjdPZjQ3TDJWOXZyLUdNR2E5ajZEUVg4bHZPSQ?oc=5","date":"2023-08-15","type":"pipeline","source":"The Business Journals","summary":"Acer Therapeutics, funded almost entirely by its own CEO, has weeks to live - The Business Journals","headline":"Acer Therapeutics, funded almost entirely by its own CEO, has weeks to live","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNQnozTlg0OHp2blpKVHd5RDZsUDBiTmxuMGNXck5aMFV3clV5YVdybXZNQ0dHUkdSVUx1QWRLXzdmVU5jcWM1bVhialM4UlpUNVN0WE5LbFpEQjdoN01Wc2RZNG1zQVREZE1tT3RNeEM5VTJtNkVwck1xeGVKTGFwaVRHVXEtdmpjRnRXUU9WNGdJdmdaNV9UcXZZMVE?oc=5","date":"2023-03-17","type":"trial","source":"Fierce Biotech","summary":"Cash-strapped Acer sees menopause drug flunk phase 2 trial - Fierce Biotech","headline":"Cash-strapped Acer sees menopause drug flunk phase 2 trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQNE1DN1hmdW9LMlpxSkthU1ZadUFsUnVhb2tmV3BDeWF0d3pRdVk0cjdma0szeHZkUzVxclBZcU1QdlRtWG1RNy1nOHRicGJiZVpCRjlRQjUtaXJtNkVMTDkwTVhKdWdFT0dody05Y0g0djhLdm5qcjQyRURqX1NaTHNmdEFtMUpBQUdRQlRTbzJqS2Q3LWNnbGR3OUxVTC1jU3FKT3pHSENzdS1MeDlnM0dTZVVHYWtkUW4tdXhKQV9IbVlVTkE?oc=5","date":"2022-12-23","type":"regulatory","source":"Reuters","summary":"U.S. FDA approves Acer Therapeutics' genetic disorder drug - Reuters","headline":"U.S. FDA approves Acer Therapeutics' genetic disorder drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPX3BlM1p4ZkY5WlA2UVFJMlUxd21VWjhDZ1h5T1d5cXpzRFhXZEpScUFRTEdHalpNSnhHYkUwMHdUSGdwT3pFdWFNRVNoYVVRdl8wM1l0ZlV5ZVl6NnFvaE11NjVpV3RzUFNqOGFMTUN5cWtydmR5UmFYcTFUdDBWaVl6VktsRUttNV95MG5pUkt0ZlExZzNMdVpDTHNDNnd4X1lVUDFjMjlMVVVpX2dkaW45aw?oc=5","date":"2022-06-27","type":"trial","source":"drugdiscoverytrends.com","summary":"Acer Therapeutics launches Phase 3 study for vascular Ehlers-Danlos syndrome - drugdiscoverytrends.com","headline":"Acer Therapeutics launches Phase 3 study for vascular Ehlers-Danlos syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPSWZvSzBYY3FHaEctd2FLTnRiZEtfc0xqeXBwOWtqSlZzOUFFY1FGYjNzRFRXQkZoN1BwSENsUDJHZ1pELTRHdThHdDVBLWoyTXByYnRTLXdJSV9BcWJ0Y1RrcFlneTJWc0MtdVNrRDkyLWNua2U4dlo1WERKRVFZZ0hremhXWlhXX2R5aE13?oc=5","date":"2019-06-26","type":"regulatory","source":"PMLiVE","summary":"Acer Therapeutics hit by FDA filing rejection - PMLiVE","headline":"Acer Therapeutics hit by FDA filing rejection","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1UNDFsSGxmZ2VSQTBrWUl3Z3hodHNRbHh3TU1yLWoyNXZVV2VGa3ZFNHVaeXBISjQwaE02RHVfWDFVMjFfMWhyM1hGSGtfaTlVVmc1MjdLZ2FjVVczN0tQQjJ1VjItRWRsYkZQd9IBcEFVX3lxTE5lRzhvQlF0emRjUkdRbVJTWHFZdnkzRFhRMExjSmFNWUNVNEpoRGtVb1FpR0FaNVRQVm0yVFpkelh5LUVXQW1vTVlFQlRsWWpoQU5qdnZkZHJGcS02cFRoclllUHdWamt0UzBCUmVkeWc?oc=5","date":"2018-10-31","type":"regulatory","source":"koreabiomed.com","summary":"Acer submits new drug application for rare disease to FDA - koreabiomed.com","headline":"Acer submits new drug application for rare disease to FDA","sentiment":"neutral"}],"patents":[{"drugName":"ACER-001","drugSlug":"sodium-phenylacetate-and-sodium-benzoate","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BioMarin Pharmaceutical Inc.","Plexus Corp.","Sarepta Therapeutics Inc."],"therapeuticFocus":["Rare Metabolic Diseases","Orphan Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":1260000,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":1260000,"period":"2021-12-31"},{"value":1260000,"period":"2021-12-31"},{"value":0,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11924837,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-26237315,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":11624226,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}